Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Inside the Lab Technology and innovation, Oncology

Faster Than a Speeding Biopsy

As our population ages and cancer becomes increasingly prevalent, researchers are always looking for faster (and earlier) ways of detecting tumor growth. The multi-cancer early detection (MCED) test – capable of detecting 50 types of cancer – has previously demonstrated the ability to use circulating cancer DNA to identify the tumor’s site of origin. Now, new research has demonstrated that it can also effectively detect and identify cases of undiagnosed cancer, too (1).

MCED uses a combination of cfDNA and machine learning to locate the origin of a cancer signal. In this case, researchers tested an early version of MCED technology on 6,621 individuals; the technology detected cancer in 1.4 percent of participants (92 patients). Of those identified, cancer was confirmed in 38 percent (35 patients), with a further 73 percent receiving diagnostic resolution within three months.

The study’s findings were presented at the 2022 ESMO Congress, where commentators were keen to emphasize the potential benefits of this new form of diagnostic test. However, they also cautioned that fully bringing MCED into the clinic would require a significant boost to both infrastructure and training in upcoming years.

Earlier this year, a separate study to evaluate the potential of MCED in clinical settings began and is still ongoing (2). Using the infrastructure of the NHS, the study is currently enrolling 140,000 patients from a pool of over one million Brits. The invited patients are aged 50–77 and are digitally selected from certain regions of the country.

Image Credit : Los Muertos Crew / Pexels.com

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. D Schrag, “A prospective study of a multi-cancer early detection blood test.” Presented at ESMO Congress 2022; September 11, 2022; Paris, France. Abstract #903O.
  2. C Swanton et al., J Clin Oncol, 40, TPS6606 (2022).
About the Author
George Francis Lee

Associate Editor, The Pathologist

Like most people, I didn’t know exactly what I wanted to do after university. But one thing was certain – writing would play a central role. Not one to walk the path most traveled, I decided to spend my next few years freelancing to hone my skills as a writer and further cement my love for language. Reaching people through writing is important to me and I look forward to connecting with thousands of people through Texere’s passionate audience.

Related Application Notes
Get the most out of your slides with the VS200 slide scanner

| Contributed by Evident Scientific

The next generation of advanced staining

| Contributed by Sakura

Voriconazole Measurement Using Fully Automated LC-MS/MS System and Comparison of Measurement Methods

| Contributed by Shimadzu

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register